Liraglutide for Adolescent Obesity: The Pediatric Evidence

Liraglutide

-4.64% BMI

Estimated treatment difference between liraglutide and placebo in adolescent BMI change at 56 weeks, in the SCALE Teens trial.

Kelly et al., NEJM, 2020

Kelly et al., NEJM, 2020

View as image

Liraglutide became the first GLP-1 receptor agonist approved for adolescent obesity in December 2020, marking a turning point in pediatric weight management. Before that approval, no pharmacological obesity treatment had received FDA clearance for adolescents in over a decade. The evidence behind that decision, and the trials that have followed, tell a more nuanced story than simple approval headlines suggest. As the broader conversation about GLP-1 drugs for teens continues to evolve, liraglutide's pediatric data remains the most mature dataset available for any incretin-based obesity therapy in young people.

This article covers every major pediatric liraglutide trial published to date: the pivotal SCALE Teens trial in adolescents, the SCALE Kids trial that extended evidence to children as young as 6, the pharmacokinetic studies that preceded both, the meta-analyses that pooled the data, and the post-hoc analyses that examined who responds best. It also covers what happens when treatment stops, how liraglutide compares to newer agents, and the safety questions that remain open in growing bodies.

How Liraglutide Works as a GLP-1 Receptor Agonist

Liraglutide is a modified version of human GLP-1, a 30-amino-acid peptide hormone released from intestinal L-cells after eating. Native GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) within approximately 2 minutes of secretion. Liraglutide's key structural modification, a C-16 fatty acid chain (palmitic acid) attached via a glutamic acid spacer at position 26, allows the molecule to bind albumin in the bloodstream. This albumin binding shields liraglutide from DPP-4 degradation and extends its half-life to roughly 13 hours, making once-daily subcutaneous injection practical.^[1]

At the receptor level, liraglutide activates GLP-1 receptors distributed across multiple organ systems. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release. In the hypothalamus, it activates anorexigenic (appetite-reducing) neurons in the arcuate nucleus while suppressing orexigenic (appetite-stimulating) pathways, producing the sustained appetite reduction that drives weight loss. In the gastrointestinal tract, it slows gastric emptying, contributing to earlier satiety. Holst's 2024 review of GLP-1 physiology in obesity details how incretin-based drugs exploit these pathways for chronic weight management.^[2]

The same mechanism that produces weight loss also causes the most common side effect: gastrointestinal discomfort. Nausea, vomiting, and diarrhea stem from the drug's effects on gastric motility and central nausea circuits. This is why liraglutide requires gradual dose escalation over 4-5 weeks, starting at 0.6 mg and increasing by 0.6 mg weekly until reaching the target dose of 3.0 mg. In pediatric populations, these effects are generally consistent with adult data, though rates vary across age groups.

The SCALE Teens Trial: Liraglutide in Adolescents Aged 12-17

The pivotal trial that led to FDA approval was the SCALE Teens study, a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2020. Kelly and colleagues enrolled 251 adolescents aged 12 to under 18 with obesity and an inadequate response to lifestyle therapy alone.^[3]

Participants were randomized to liraglutide 3.0 mg (or maximum tolerated dose) or placebo, both combined with lifestyle intervention, for 56 weeks with a subsequent 26-week follow-up period off treatment.

Primary results

The primary endpoint was change from baseline in BMI standard deviation score (BMI SDS) at week 56. Liraglutide produced a significantly greater reduction in BMI SDS than placebo. The estimated treatment difference was -0.22 (95% CI: -0.37 to -0.08; P = 0.002).

Translated into more intuitive metrics:

• BMI change: -4.64 percentage points difference favoring liraglutide
• Body weight change: -4.50 kg difference, or -5.01 percentage points
• Clinically meaningful response: 43.3% of liraglutide-treated adolescents achieved at least 5% BMI reduction versus 18.7% with placebo

Safety profile

Gastrointestinal adverse events occurred in 64.8% of the liraglutide group versus 36.5% of placebo. Nausea was the most frequently reported event. Adverse events leading to treatment discontinuation occurred in 10.4% of liraglutide-treated participants versus none in the placebo group.

Critically for a pediatric population, there were no apparent differences between groups in growth, pubertal development, or bone age. One suicide occurred in the liraglutide treatment group, which prompted inclusion of monitoring recommendations in the label. For a deeper examination of the long-term safety profile, see liraglutide long-term safety data.

The follow-up period

During the 26-week off-treatment follow-up, weight regain occurred in the liraglutide group, eroding much of the treatment benefit. By the end of the follow-up, the BMI SDS difference between groups had narrowed substantially. This pattern mirrors adult data and raises fundamental questions about treatment duration in pediatric obesity management.

Putting the numbers in context

A 4.64 percentage point BMI difference may sound modest. To put it in clinical perspective: for a 15-year-old male at the 99th percentile for BMI, a 5% BMI reduction can shift metabolic risk markers, reduce insulin resistance, and begin to reverse the trajectory toward type 2 diabetes. The SCALE Teens trial was not designed to produce dramatic weight loss; it tested whether a pharmacological intervention could meaningfully alter BMI trajectory in adolescents already failing lifestyle-only approaches. By that standard, the trial succeeded.

The SCALE Kids Trial: Extending Evidence to Children 6-11

Published in the New England Journal of Medicine in 2025, the SCALE Kids trial was the first randomized controlled trial of any GLP-1 receptor agonist in children under 12 years of age. Fox and colleagues randomized 82 children aged 6 to under 12 with obesity to liraglutide 3.0 mg or placebo (2:1 ratio), both with lifestyle interventions, for 56 weeks.^[4]

Primary results

At week 56, the mean percentage change from baseline in BMI was:

• Liraglutide: -5.8%
• Placebo: +1.6%
• Estimated difference: -7.4 percentage points (95% CI: -11.6 to -3.2; P < 0.001)

Body weight data requires careful interpretation in growing children. Children in both groups gained weight (as expected during growth), but liraglutide-treated children gained far less: 1.6% versus 10.0% body weight gain, an estimated difference of -8.4 percentage points (P = 0.001).

Nearly half (46%) of liraglutide-treated children achieved at least 5% BMI reduction versus 9% with placebo (adjusted OR 6.3; P = 0.02).

Safety considerations in younger children

Gastrointestinal adverse events were more common with liraglutide (80%) than placebo (54%). This rate is notably higher than in the adolescent SCALE Teens trial (64.8%), suggesting younger children may be more sensitive to GI effects.

Serious adverse events occurred in 12% of the liraglutide group versus 8% of placebo. The small sample size (82 total participants) limits the ability to draw conclusions about rare adverse events. Long-term effects of modulating incretin signaling during critical developmental periods remain unknown.

What the Meta-Analyses Show

Cornejo-Estrada and colleagues published a systematic review and meta-analysis in 2023 examining liraglutide's efficacy across pediatric RCTs. The analysis included 296 participants across three studies that met inclusion criteria.^[5]

Pooled results demonstrated:

• BMI SDS reduction: Pooled mean difference of -0.17 (P = 0.003)
• BMI reduction: Mean difference of 1.28 (P = 0.0008)
• Body weight reduction: Mean difference of 1.83 (P = 0.03)
• Fasting insulin: Significant reduction favoring liraglutide

A more recent meta-analysis published in Pediatric Research in 2025, incorporating data from seven randomized controlled trials with 547 participants, found liraglutide significantly reduced BMI Z-score with a standardized mean difference of -1.03. The analysis confirmed that the safety profile was similar to that seen in individual trials, with gastrointestinal events as the predominant adverse effect.

These meta-analyses consistently show statistically significant but moderate absolute effects on BMI and weight. The effect sizes are smaller than what newer GLP-1 agents like semaglutide produce in adults, but direct pediatric comparisons are limited.

Who Responds Best? Predictors of Weight Loss

Not every adolescent responds equally to liraglutide. Bensignor and colleagues performed a post-hoc analysis of the SCALE Teens trial data in 2023, attempting to identify baseline characteristics that predicted greater or lesser weight loss responses.^[6]

The analysis examined whether sex, age within the 12-17 range, baseline BMI severity, race/ethnicity, or metabolic parameters at baseline predicted treatment response. While the analysis was limited by the trial's sample size (125 liraglutide-treated adolescents), the findings suggested that liraglutide's effect was broadly consistent across subgroups.

Early response appears to be a meaningful signal. Adolescents who lost more weight in the initial 12 weeks of treatment tended to sustain greater weight reduction through week 56. This aligns with adult GLP-1 data suggesting that early non-responders are unlikely to become late responders, a clinically useful observation for deciding whether to continue therapy.

The post-hoc nature of these findings limits their strength. Prospective studies designed specifically to identify responders versus non-responders in pediatric populations have not yet been conducted.

One practical implication: if an adolescent does not show meaningful BMI reduction after 12-16 weeks at the full 3.0 mg dose, the probability of achieving a clinically significant response by week 56 is low. This "early responder" framework, if validated prospectively, could spare non-responding adolescents from months of unnecessary injections and side effects.

Safety in Growing Bodies: What the Early Trials Established

Before the pivotal SCALE Teens trial, Danne and colleagues conducted a 5-week dose-escalation study in 2017 to evaluate liraglutide's pharmacokinetics, safety, and tolerability specifically in adolescents aged 12-17.^[7]

This trial established that:

• Liraglutide's pharmacokinetic profile in adolescents was comparable to that in adults
• Dose escalation from 0.6 mg to 3.0 mg followed a similar tolerance pattern as in adults
• Gastrointestinal symptoms were the dose-limiting factor for most participants
• No unexpected safety signals emerged in the adolescent population

The safety data across all pediatric liraglutide trials can be summarized in three categories:

Expected and manageable: Gastrointestinal events (nausea, vomiting, diarrhea) affecting 60-80% of treated participants. These are generally transient, peak during dose escalation, and are the primary reason for discontinuation.

Monitored but not confirmed: Psychiatric adverse events, including one suicide in the SCALE Teens trial. The FDA label includes monitoring recommendations for depression and suicidal ideation. Whether this signal is causally related to liraglutide or reflects background rates in adolescents with obesity is not established.

Unknown: Long-term effects on growth, pubertal development, bone mineralization, and metabolic programming. The 56-week treatment periods with 26-week follow-up provide limited insight into what happens over years of use during development. For broader safety context, see liraglutide long-term safety data.

What Happens When Adolescents Stop Liraglutide

Weight regain after GLP-1 agonist discontinuation is one of the most clinically significant findings in obesity pharmacology. Quarenghi and colleagues reviewed this phenomenon across liraglutide, semaglutide, and tirzepatide in 2025, confirming that weight regain is a class-wide effect, not unique to any single agent.^[8]

In the SCALE Teens trial, the 26-week follow-up period after treatment cessation showed clear weight regain in the liraglutide group. The BMI SDS improvements achieved during treatment were partially reversed once the drug was stopped.

This finding creates a clinical dilemma in pediatric practice. If treatment must be indefinite to maintain benefit, clinicians and families face decisions about:

• Years or decades of daily injections starting in adolescence
• Unknown long-term safety in patients exposed during developmental years
• Cost sustainability of chronic therapy (for cost context, see cost-effectiveness of GLP-1s)
• Psychological implications of treatment-dependent weight maintenance

The evidence does not currently answer whether intermittent use, lower maintenance doses, or scheduled treatment breaks could preserve some benefit while reducing exposure. These questions remain open and are particularly acute in the pediatric context.

How Liraglutide Compares to Newer GLP-1 Agents in Young People

Liraglutide was the first GLP-1 receptor agonist to accumulate substantial pediatric data, but it is no longer the most potent option. Semaglutide (Wegovy), which activates the same GLP-1 receptor with greater binding affinity and a weekly dosing schedule, has produced larger weight reductions in adolescent trials.

Van Boxel and colleagues published observational data in 2024 on semaglutide treatment in children with obesity, providing early real-world evidence in younger populations.^[9] While direct head-to-head pediatric trials comparing liraglutide and semaglutide are limited, the adult comparison data consistently shows semaglutide producing roughly double the weight loss of liraglutide at maximum doses.

This raises the question of where liraglutide fits in the evolving treatment landscape. For a detailed comparison, see liraglutide vs semaglutide and whether Saxenda is still worth it in 2026.

Key considerations include:

• Data maturity: Liraglutide has the longest pediatric safety dataset of any GLP-1 agonist
• Dosing frequency: Daily injection (liraglutide) versus weekly (semaglutide), which matters for adolescent adherence
• Efficacy gap: Semaglutide likely produces greater weight loss, though pediatric head-to-head data is limited
• Regulatory status: Liraglutide approved for ages 12+; semaglutide's pediatric indication followed later

Chu and colleagues documented the rapid increase in GLP-1 receptor agonist dispensing among youth with type 2 diabetes between 2020 and 2023, reflecting the expanding role of these drugs in pediatric practice.^[10]

The FDA Approval: What Changed in December 2020

The FDA's supplemental approval of Saxenda for adolescents aged 12 and older on December 4, 2020 was based primarily on the SCALE Teens trial data. The approval specified:

• Age range: 12 years and older
• BMI threshold: Obesity, defined by age- and sex-specific BMI cutoffs corresponding to adult BMI of 30 kg/m2 or higher
• Weight requirement: Body weight above 60 kg (132 pounds)
• Use context: Adjunct to reduced-calorie diet and increased physical activity

The label includes warnings about thyroid C-cell tumors (based on rodent data), pancreatitis, gallbladder disease, and monitoring for psychiatric adverse events including suicidal behavior.

This approval made Saxenda the first FDA-approved weight management therapy for adolescents in over a decade. The previous approved option, orlistat, had limited efficacy and poor tolerability in adolescents. Liraglutide's approval established a regulatory pathway that subsequent GLP-1 agonists have followed for pediatric obesity indications.

Since the approval, prescriptions for obesity medications in adolescents have increased substantially. CDC data from MMWR showed that GLP-1 receptor agonist prescriptions among adolescents aged 12-17 with obesity rose markedly between 2020 and 2023, driven primarily by liraglutide and later semaglutide. This trend reflects both the growing acceptance of pharmacological intervention for adolescent obesity and the shifting clinical consensus that lifestyle modification alone is insufficient for many patients with severe obesity.

For a broader look at where liraglutide fits relative to newer options, see liraglutide (Saxenda) for weight loss and how it compares to newer GLP-1s.

Beyond Weight: Metabolic Effects in Adolescents

Liraglutide's effects in adolescents extend beyond the scale. Across trials, treated adolescents showed improvements in:

• Fasting insulin levels: Significant reductions, suggesting improved insulin sensitivity
• Glycated hemoglobin (HbA1c): Modest improvements, relevant given that many adolescents with severe obesity have prediabetes
• Systolic blood pressure: Reductions observed in the SCALE Teens trial
• Cardiovascular risk markers: Adult data shows liraglutide's cardiovascular benefits (see GLP-1 drugs and heart disease), though pediatric cardiovascular outcome data does not exist^[11]

Whether these metabolic improvements translate into long-term cardiovascular benefit when treatment is initiated in adolescence, and potentially discontinued years later, is unknown. The natural history of treated versus untreated adolescent obesity diverges over decades, and no trial has followed pediatric liraglutide patients long enough to capture hard cardiovascular endpoints.

What the Evidence Does Not Answer

Several critical questions remain unresolved in the pediatric liraglutide evidence base:

Optimal treatment duration: No trial has tested treatment periods longer than 56 weeks. Whether indefinite treatment is necessary, and what happens after 2, 5, or 10 years of use in growing patients, is entirely unknown.

Effects on growth and development: The 56-week trials showed no differences in pubertal development or bone age. Whether this holds over years of treatment during adolescence cannot be determined from existing data.

Combination approaches: Whether liraglutide combined with behavioral interventions produces durable effects even after drug discontinuation has not been studied in isolation from the lifestyle component of existing trials.

Equity and access: The cost of daily liraglutide injections creates access barriers. Adolescents from lower-income backgrounds, who carry a disproportionate burden of obesity, are least likely to access treatment. Chu et al.'s dispensing data suggests that utilization patterns may not align with need.^[10]

Psychological effects: Tempia and colleagues identified associations between psychiatric symptoms and liraglutide therapy adherence in adults, raising questions about how these dynamics play out in adolescents.^[12] The intersection of obesity, body image, and medication use during adolescent identity development is complex and understudied. For related discussion, see body image after GLP-1 weight loss.

The Bottom Line

Liraglutide is the most extensively studied GLP-1 receptor agonist in pediatric obesity, with RCT data spanning ages 6 through 17. The evidence shows consistent, statistically significant BMI reductions across age groups, with effect sizes moderate compared to adult data or newer agents. Safety data is reassuring over 56-week treatment periods but uninformative about long-term use during development. The weight regain observed after discontinuation, combined with the absence of data on extended treatment in young patients, leaves clinicians navigating between proven short-term efficacy and uncharted long-term territory.

Frequently Asked Questions

Is liraglutide FDA approved for teenagers?

Yes. The FDA approved Saxenda (liraglutide 3.0 mg) for chronic weight management in patients aged 12 and older with obesity in December 2020. Approval was based on the SCALE Teens trial of 251 adolescents, which showed a 4.64 percentage point greater BMI reduction versus placebo over 56 weeks. Patients must have a BMI meeting age/sex-specific obesity thresholds and weigh more than 60 kg.

How much weight do adolescents lose on liraglutide?

In the SCALE Teens trial, adolescents on liraglutide 3.0 mg lost an average of 4.50 kg more than those on placebo over 56 weeks, representing a 5.01 percentage point difference in body weight change. About 43% of treated adolescents achieved at least 5% BMI reduction compared to 19% with placebo. Individual responses vary; early weight loss in the first 12 weeks may predict long-term response.

What are the side effects of liraglutide in children?

Gastrointestinal effects are the primary concern. In the adolescent trial, 64.8% experienced GI events (nausea, vomiting, diarrhea) versus 36.5% with placebo. In children aged 6-11, GI rates were higher at 80% versus 54%. These symptoms typically peak during dose escalation and often diminish over time. Serious adverse events occurred at similar rates between groups in both trials.

Does liraglutide work for children under 12?

The SCALE Kids trial (Fox et al., NEJM 2025) tested liraglutide in 82 children aged 6-11. After 56 weeks, treated children saw BMI decrease by 5.8% versus a 1.6% increase with placebo, a 7.4 percentage point difference. However, liraglutide is not yet FDA-approved for children under 12. The small sample size and short duration leave questions about long-term safety in this younger age group.

Do teens gain weight back after stopping liraglutide?

Yes. In the SCALE Teens trial, weight regain occurred during the 26-week follow-up period after stopping treatment. This pattern is consistent across GLP-1 receptor agonists in both adolescent and adult studies. The finding raises questions about whether treatment needs to be indefinite for sustained benefit, a decision with particular complexity in pediatric patients who face decades of potential use.

Is semaglutide better than liraglutide for teen obesity?

Direct head-to-head pediatric trials are limited, but adult data consistently shows semaglutide producing roughly double the weight loss of liraglutide. Semaglutide also offers weekly dosing versus daily for liraglutide, which may improve adolescent adherence. Liraglutide's advantage is its longer pediatric safety track record and earlier FDA approval for the 12+ age group.